The EU Joint Clinical Assessment: Benefits & Drawbacks

David Aitken 

Joint Clinical Assessment (JCA): A harmonised approach to clinical assessments across the European Union

In January 2022, the European Commission published a milestone regulation enforcing a joint approach to clinical assessments across the European Union. This joint clinical assessment (JCA) of technologies will begin with oncology therapies in January 2025. Here, we outline the upcoming JCA process and give some thoughts to its benefits and drawbacks. At HEOR, we look forward to using our HTA experience to support our clients in strategically navigating this new landscape and aiding patient access to life-changing medicines.

Click here to download the full white paper. 

More insights

 
Beyond the genome: why patients matter as much as the data
The future of genomic medicine will be shaped not just by the data we generate, but by how well we help patients understand and benefit from it
 
Genomic screening: proving value beyond early diagnosis
The success of genomic screening will depend not only on what it can detect, but on whether acting on that information delivers meaningful value
 
Building a genomics-ready NHS: the implementation challenge
The question is no longer whether genomics can improve healthcare. Increasingly, the challenge is whether healthcare systems are equipped to use genomic information effectively
 
Obesity, employment, and economic productivity in Europe: a systematic literature review 
Alexandra Furber, Senior Systematic Reviewer at HEOR, explains the motivation behind the research and provides further insight into the findings